Details for New Drug Application (NDA): 216660
✉ Email this page to a colleague
The generic ingredient in RELYVRIO is sodium phenylbutyrate; taurursodiol. There are one thousand four hundred and seventy-two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the sodium phenylbutyrate; taurursodiol profile page.
Summary for 216660
Tradename: | RELYVRIO |
Applicant: | Amylyx |
Ingredient: | sodium phenylbutyrate; taurursodiol |
Patents: | 5 |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for 216660
Generic Entry Date for 216660*:
Constraining patent/regulatory exclusivity:
TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) IN ADULTS Dosage:
FOR SUSPENSION;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for NDA: 216660
Mechanism of Action | Ammonium Ion Binding Activity |
Suppliers and Packaging for NDA: 216660
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
RELYVRIO | sodium phenylbutyrate; taurursodiol | FOR SUSPENSION;ORAL | 216660 | NDA | Amylyx Pharmaceuticals Inc | 73063-035 | 73063-035-03 | 56 POWDER, FOR SUSPENSION in 1 CARTON (73063-035-03) |
RELYVRIO | sodium phenylbutyrate; taurursodiol | FOR SUSPENSION;ORAL | 216660 | NDA | Amylyx Pharmaceuticals Inc | 73063-035 | 73063-035-04 | 7 POWDER, FOR SUSPENSION in 1 CARTON (73063-035-04) |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | FOR SUSPENSION;ORAL | Strength | 3GM/PACKET; 1GM/PACKET | ||||
Approval Date: | Sep 29, 2022 | TE: | RLD: | Yes | |||||
Regulatory Exclusivity Expiration: | Sep 29, 2027 | ||||||||
Regulatory Exclusivity Use: | NEW CHEMICAL ENTITY | ||||||||
Regulatory Exclusivity Expiration: | Sep 29, 2029 | ||||||||
Regulatory Exclusivity Use: | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) IN ADULTS | ||||||||
Patent: | ⤷ Sign Up | Patent Expiration: | Dec 24, 2033 | Product Flag? | Substance Flag? | Delist Request? | |||
Patented Use: | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) IN ADULTS |
Complete Access Available with Subscription